200 related articles for article (PubMed ID: 20816538)
1. Antitrypanosomal agents: treatment or threat?
Issa VS; Bocchi EA
Lancet; 2010 Sep; 376(9743):768; author reply 768-9. PubMed ID: 20816538
[No Abstract] [Full Text] [Related]
2. Potential new clinical therapies for Chagas disease.
Bustamante JM; Tarleton RL
Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
[TBL] [Abstract][Full Text] [Related]
3. [Nifurtimox, a bright future for treatment of Chagas disease].
Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
[TBL] [Abstract][Full Text] [Related]
4. Antitrypanosomal therapy for chronic Chagas' disease.
Bern C
N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
[No Abstract] [Full Text] [Related]
5. [Treatment of Chagas' disease].
Apt W
Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
[No Abstract] [Full Text] [Related]
6. [Allopurinol in the treatment of chronic Chagas' disease].
Meirovich CI; Montrull HL; Gallerano RH; Sosa RR
Arq Bras Cardiol; 1985 Sep; 45(3):217-23. PubMed ID: 3939099
[No Abstract] [Full Text] [Related]
7. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease.
Alvarez MG; Vigliano C; Lococo B; Petti M; Bertocchi G; Viotti R
Trans R Soc Trop Med Hyg; 2012 Oct; 106(10):636-8. PubMed ID: 22898619
[TBL] [Abstract][Full Text] [Related]
8. Chagas' disease.
Montero A; Giovannoni AG
Lancet; 2001 Jul; 358(9275):74. PubMed ID: 11458940
[No Abstract] [Full Text] [Related]
9. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
[TBL] [Abstract][Full Text] [Related]
10. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
Murcia L; Carrilero B; Albajar Viñas P; Segovia M
Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
[No Abstract] [Full Text] [Related]
11. [Chagas' disease: clastogenic effect of nifurtimox and benznidazole in children].
Moya PR; Trombotto GT
Medicina (B Aires); 1988; 48(5):487-91. PubMed ID: 3151216
[No Abstract] [Full Text] [Related]
12. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
13. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
Cevey ÁC; Mirkin GA; Penas FN; Goren NB
Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
[TBL] [Abstract][Full Text] [Related]
14. First century of Chagas' disease: an overview on novel approaches to nifurtimox and benzonidazole delivery systems.
Salomon CJ
J Pharm Sci; 2012 Mar; 101(3):888-94. PubMed ID: 22161779
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina.
Sosa Estani S; Segura EL
Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():363-5. PubMed ID: 10677756
[No Abstract] [Full Text] [Related]
16. Current status of Chagas disease chemotherapy.
Guedes PM; Silva GK; Gutierrez FR; Silva JS
Expert Rev Anti Infect Ther; 2011 May; 9(5):609-20. PubMed ID: 21609270
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.
Cencig S; Coltel N; Truyens C; Carlier Y
Int J Antimicrob Agents; 2012 Dec; 40(6):527-32. PubMed ID: 23063742
[TBL] [Abstract][Full Text] [Related]
18. The present situation, challenges, and perspectives regarding the production and utilization of effective drugs against human Chagas disease.
Dias JC; Coura JR; Yasuda MA
Rev Soc Bras Med Trop; 2014; 47(1):123-5. PubMed ID: 24603750
[No Abstract] [Full Text] [Related]
19. [Peripheral polyneuropathy induced by benzonidazole in the treatment of Chagas' disease].
Defaria CR; De Melo-Souza SE; Rassi A
Arq Neuropsiquiatr; 1986 Jun; 44(2):125-9. PubMed ID: 3099734
[TBL] [Abstract][Full Text] [Related]
20. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.
Garcia-Bournissen F; Altcheh J; Giglio N; Mastrantonio G; Della Védova CO; Koren G
Paediatr Drugs; 2009; 11(1):33-7. PubMed ID: 19127950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
